VEGFR2-IN-2（Cat No.:I043521）is a small-molecule inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR2), a key protein involved in angiogenesis, the process of forming new blood vessels. By blocking VEGFR2, VEGFR2-IN-2 aims to inhibit tumor blood supply, which is crucial for the growth and metastasis of cancer cells. It has shown promise in preclinical studies as a potential anti-cancer agent, particularly for solid tumors such as breast, lung, and colorectal cancers. This inhibitor’s ability to target the angiogenesis pathway positions it as a valuable tool in cancer therapy development.